- Multicenter Study Evaluates Trend Accuracy of Noninvasive, Continuous Masimo SpHb® and Two Invasive Hemoglobin Testing Methods
- Masimo to Present at Evercore ISI 2nd Annual HealthCONx Conference
- Masimo to Present at Piper Jaffray 31st Annual Healthcare Conference
- Study Uses Masimo Patient SafetyNet™ and rainbow Acoustic Monitoring® to Investigate the Incidence of Desaturation and Bradypnea in Postoperative Patients
- Masimo to Present at Stifel 2019 Healthcare Conference
- Masimo Announces CE Marking of Radius Capnography™ for the Root® Patient Monitoring and Connectivity Platform
- Masimo Reports Third Quarter 2019 Financial Results
- Study Investigates Effects of Masimo SpHb®, Noninvasive and Continuous Hemoglobin Monitoring, on Postoperative Anemia and Inappropriate Blood Transfusion in Patients Undergoing Hip and Knee Surgery
- Masimo to Report Third Quarter 2019 Financial Results after Market Close on Wednesday, October 30
- Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes
Masimo Corp (MASI:NSQ) closed at 152.21, -5.02% below its 52-week high of 160.25, set on Jul 31, 2019.
98.23Dec 24 2018160.25Jul 31 2019
Markit short selling activity
|Market cap||8.34bn USD|
|EPS (TTM)||3.39 |
Data delayed at least 15 minutes, as of Dec 09 2019 21:00 GMT.